Safety and Efficacy of Adding Nalbuphine to Bupivacaine in Transversus Abdominis Plane Block in Laparoscopic Bariatric Surgery: A Randomised Controlled Trial.

Efficacy of Nalbuphine in TAP Block

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202208575341765

Enrollment

Registered

2022-08-23

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery Anaesthesia

Interventions

TAP block with plain bupivacaine

TAP block with bupivacaine with nalbuphine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obese patients with BMI = 35 kg/m2 Obese patients aged between 19 and 65 years of age Elective laparoscopic bariatric surgery. American Society of Anesthesiology physical status II and III

Exclusion criteria

Exclusion criteria: Known allergy to nalbuphine and/or Bupivacaine Chronic opioid users Chronic pain conditions (consuming regular analgesics > 3 months) History of neurological diseases

Design outcomes

Primary

Measure	Time frame
The time to first full ambulation	—

Secondary

Measure	Time frame
a. Hemodynamic monitoring ;b. First time to request analgesic post-operative;d. Visual analogue score (VAS) ;e. Total opioid consumption;g. Time of hospital stay.	—

Countries

Egypt

Contacts

Public ContactMohamed Mahmoud

Associate professor Cairo University

mohamed_mahmoud@kasralainy.edu.eg+201003714635

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026